Principle Wealth Partners LLC Purchases 510 Shares of Novo Nordisk A/S (NYSE:NVO)

Principle Wealth Partners LLC grew its position in Novo Nordisk A/S (NYSE:NVO) by 12.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 4,502 shares of the company’s stock after acquiring an additional 510 shares during the quarter. Principle Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $387,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Natixis Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after buying an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC boosted its holdings in shares of Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after buying an additional 19,870 shares in the last quarter. Versant Capital Management Inc bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $86,000. Talbot Financial LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter worth approximately $4,066,000. Finally, Clear Creek Financial Management LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter worth approximately $450,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

NVO opened at $83.78 on Wednesday. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $375.95 billion, a PE ratio of 25.46, a P/E/G ratio of 0.96 and a beta of 0.45. The firm has a 50 day moving average of $90.96 and a two-hundred day moving average of $110.91.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, analysts anticipate that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s payout ratio is 47.72%.

Analyst Ratings Changes

A number of analysts recently commented on the stock. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.